Aeterna Zentaris: Surges on progress in COVID-19 vaccine development

COSCIENS Biopharma

02/02/2021 13:38

** U.S.-listed shares of Canadian biopharmaceutical company
 AEZS.TO  up 45.7% pre-market at $1.01 per share - a seven month
high
    ** Co announces evaluation and potential development of an
oral prophylactic bacterial vaccine against COVID-19
 urn:newsml:reuters.com:*:nGNX7tyf4H
    ** Vaccine developed through an exclusive option agreement
with Julius-Maximilians-University of Wurzburg
    ** The vaccine platform technology is undergoing
pre-clinical studies 
    ** Up to Monday's close, stock had risen nearly 65%; the
second best performer among its peers after Helix Biopharma Corp
 HBP.TO , which jumped 94%

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))